Journal

STEADRIGHT FOLLOWS UP ON DISTRICT SIZE NICKEL-COPPER- COBALT POTENTIAL

Retrieved on: 
Monday, January 23, 2023
Duluth Complex, National Instrument 43-101, Journal, Cobalt, SCM, Mining, National instrument, TSX, NL, B-20, RAM, CSE, Massive, Anomaly, Royal Canadian Institute, EM, National Strategic and Critical Minerals Production Act of 2013, Port-Cartier, Nickel, Copper

Huntsville, ONT., Jan. 23, 2023 (GLOBE NEWSWIRE) --

Key Points: 
  • Steadright Critical Minerals (CSE: SCM) (“Steadright” or the “Company”) is pleased to announce that Steadright’s exploration team has compiled historical information on the highly prospective RAM project near Port Cartier, Quebec, which is associated with Nickel-Copper-Cobalt mineralization.
  • The RAM project has a strike length of over 9km on the “Main Block” area and a 2km splay with both up to 500 meters wide and open at depth.
  • The entire strike length currently contains, “Drill Ready” targets based on the alignment of the magnetic, gravity, ground and airborne EM anomalies coincident with identified geological targets.
  • The system is characterized by several zones over 20 meters thick that are possibly related to a 60-meter-thick zone defined by earlier drilling.

Phase 1 Clinical Data of Milademetan Published in Journal of Clinical Oncology

Retrieved on: 
Monday, January 23, 2023
Bachelor of Medicine, Bachelor of Surgery, MANTRA, Journal, MD, Patient, DD, MDM4, CDK4, Journal of Clinical Oncology, Cytopenia, Biomarker, Therapy, Neoplasm, RAIN, Progression-free survival, RNA transfection, Doctor of Philosophy, MDM2, Pharmaceutical industry

NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Rain Oncology Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics with its lead product candidate, milademetan, an oral, small molecule inhibitor of the p53-MDM2 complex that reactivates p53, today announced the publication of a peer-reviewed article titled, “A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients with Advanced Liposarcoma, Solid Tumors or Lymphomas” in the Journal of Clinical Oncology. Phase 1 clinical data in the paper highlight the activity and tolerability using intermittent dosing of milademetan across a range of tumor types including dedifferentiated liposarcoma (DD LPS), which represented the largest proportion of patients enrolled in the study (n=53).

Key Points: 
  • Phase 1 clinical data in the paper highlight the activity and tolerability using intermittent dosing of milademetan across a range of tumor types including dedifferentiated liposarcoma (DD LPS), which represented the largest proportion of patients enrolled in the study (n=53).
  • “An intermittent dosing schedule (260 mg qd, 3/14 days) of our highly selective inhibitor of the p53-MDM2 complex, milademetan, resulted in favorable safety and clinical activity in the Phase 1 trial in DD LPS patients,” said Robert Doebele, MD, Ph.D., co-founder, president and chief scientific officer of Rain.
  • The preferred intermittent dosing schedule of milademetan (260 mg qd 3/14 days) mitigates dose-limiting hematologic adverse events while maintaining activity, leading to:
    Fewer dose reductions (21.1%; n=8) and dose interruptions (15.8%; n=6) compared with extended/continuous schedules (23.3%; n=16 and 34.8%; n=24, respectively).
  • Preliminary single-agent activity with milademetan in DD LPS prompted the ongoing, randomized Phase 3 MANTRA trial (NCT04979442), with topline data anticipated in the first quarter of 2023.

BioSig Issues Shareholder Update to Highlight Recent Achievements and Ongoing Developments

Retrieved on: 
Thursday, January 19, 2023
Cleveland Clinic, Congress, EP, Hospital, Trust, Electrophysiology, Arrhythmia, History, Atrial fibrillation, Innovation, PURE, Cleveland, Medtech, HFA, Journal, Research, Science, Bellin Health, Letter, Version 6 Unix, Physician, Health, Pharmaceutical industry, Renewable energy, Nautilus, Inc. v. Biosig Instruments, Inc.

BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today issued an update to shareholders highlighting recent milestones and ongoing company developments.

Key Points: 
  • BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”) an advanced digital signal processing technology company delivering unprecedented accuracy and precision to intracardiac signal visualization with its proprietary PURE EP™ System, today issued an update to shareholders highlighting recent milestones and ongoing company developments.
  • These are milestones never seen before at BioSig and we believe there are many more exciting ones ahead.
  • We are confident that BioSig will be one of those emerging leaders based on the exciting commercial, technology and corporate activities underway in 2023.
  • At BioSig, we understand the importance of personalized patient care and the economic squeeze of making every clinical decision count.

Industry IoT Consortium Publishes Latest Edition of Journal of Innovation

Retrieved on: 
Thursday, January 19, 2023
Augmented reality, Object Management Group, Digital transformation, Internet, AI, Carbon, Enterprise, Organization, OMG, City, IIC, Journal, International Journal of Innovation and Technology Management, Innovation, Role, Joi, Industrial internet of things, New Frontier, Cryptocurrency, Video game console, Exchange, Industrial

BOSTON, MA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The Industry IoT Consortium® (IIC™) today published the newest edition of the Journal of Innovation (JoI) entitled, Business Outcomes of Utilizing Innovative Technologies in Industrial IoT.

Key Points: 
  • BOSTON, MA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- The Industry IoT Consortium® (IIC™) today published the newest edition of the Journal of Innovation (JoI) entitled, Business Outcomes of Utilizing Innovative Technologies in Industrial IoT.
  • The Industry IoT Consortium delivers transformative business value to industry, organizations, and society by accelerating the adoption of a trustworthy internet of things.
  • The Industry IoT Consortium is a program of the Object Management Group® (OMG®).
  • Note to editors: Industry IoT Consortium is a registered trademark, and IIC is a trademark of OMG.

Bloomberg Tax Announces 2022 Recipients of Outstanding Author Awards for Estates, Gifts, and Trusts

Retrieved on: 
Wednesday, January 18, 2023
Trust, IRS, Transfer, American College of Trust and Estate Counsel, Estate, University of Miami School of Law, Withers LLP, Starlink, PL, Goldstein, Drake University Law School, Estate planning, University, Publication, Private practice, Common Wealth Award of Distinguished Service, American College, Inheritance tax, New York University School of Law, Lawyer, Physician, Senior advisor, Counsel, Author, National Association, LLP, Book, Law, Florida International University School of Architecture, SLAT, Spouse, Journal, LLM, Life insurance, Property management, Gassman

ARLINGTON, Va., Jan. 18, 2023 /PRNewswire/ -- Bloomberg Tax & Accounting today announced its 2022 honorees for outstanding authorship in estates, gifts, and trusts and the recipient of the 2022 Leonard L. Silverstein Award for Distinguished Service in Estates, Gifts, and Trusts Taxation. The awards were presented at a luncheon at the 57th Annual Heckerling Institute on Estate Planning, which took place in Orlando from January 9-13.

Key Points: 
  • ARLINGTON, Va., Jan. 18, 2023 /PRNewswire/ -- Bloomberg Tax & Accounting today announced its 2022 honorees for outstanding authorship in estates, gifts, and trusts and the recipient of the 2022 Leonard L. Silverstein Award for Distinguished Service in Estates, Gifts, and Trusts Taxation.
  • The awards were presented at a luncheon at the 57th Annual Heckerling Institute on Estate Planning, which took place in Orlando from January 9-13.
  • Michelle Graham was named the Tax Portfolio Author of the Year award for her work on Portfolio 842 T.M., Transfers to Noncitizen Spouses.
  • He was the lead author on Bloomberg Tax's Estate Tax Planning in 2011 and 2012 and has published many additional resources on trusts and tax planning.

New Study Shows Vasc-Alert Surveillance Technology Successfully Predicts Vascular Access Blockages in Dialysis Patients

Retrieved on: 
Wednesday, January 18, 2023
Kidney, Failure, McKinsey & Company, Henry Ford Hospital, Stenosis, Dialysis, WEST, AV, Death, Patient, Health care, Journal, Thrombosis, Incidence, Ascension St. Mary's Hospital, Pharmaceutical industry, Medical device, Medical imaging, Health insurance

WEST LAFAYETTE, Ind., Jan. 18, 2023 /PRNewswire/ -- Vasc-Alert, a pioneer in vascular access surveillance, today announced the publication of a study in the Journal of Vascular Access validating its Vasc-Alert surveillance technology for dialysis patients.

Key Points: 
  • Technology provides great value for patients, staff, and the healthcare system and should become standard of care, study authors say
    WEST LAFAYETTE, Ind., Jan. 18, 2023 /PRNewswire/ -- Vasc-Alert, a pioneer in vascular access surveillance, today announced the publication of a study in the Journal of Vascular Access validating its Vasc-Alert surveillance technology for dialysis patients.
  • The study shows that the technology reliably predicts which patients may suffer from stenosis, or blockage, in their access – and may even be better than clinical monitoring alone.
  • The study, at Henry Ford Hospital in Detroit, examined 38 patients who were receiving dialysis through an arteriovenous (AV) access.
  • The technology works by using data that's already collected by the dialysis machines, such as arterial and venous pressures, to derive the pressures in the vascular access.

AposHealth® Announces the Addition of Chief Medical Officer Harry L. Leider, MD, MBA to Their Executive Leadership Team

Retrieved on: 
Tuesday, January 17, 2023
Population Health Management, Biotechnology, EVP, MD, FDA, Organization, Population health, UnitedHealth Group, Therapy, Knee, Journal, Medicine, CMO, MBA, Physician Executive, Obesity, Pharmaceutical industry, Management, Walgreens

NEW YORK, Jan. 17, 2023 /PRNewswire/ -- AposHealth, a medical device company providing first-in-class solutions to treat musculoskeletal conditions, today announced the appointment of Harry L. Leider, MD, MBA as its new Chief Medical Officer (CMO) and Executive Vice President.

Key Points: 
  • NEW YORK, Jan. 17, 2023 /PRNewswire/ -- AposHealth, a medical device company providing first-in-class solutions to treat musculoskeletal conditions, today announced the appointment of Harry L. Leider, MD, MBA as its new Chief Medical Officer (CMO) and Executive Vice President.
  • "Harry's commercial and clinical expertise, along with his strategic business perspective, will be instrumental in advancing AposHealth on our continued commercial success."
  • Prior to joining AposHealth, Dr. Leider served as the CMO of Gelesis, a biotechnology company that commercialized an FDA-cleared medical device to treat obesity.
  • "Apos® represents an entirely new category of therapeutics for treating common and costly musculoskeletal conditions such as chronic osteoarthritis of the knee.

Chung-Ang University Researchers Evaluate Mass Spectrometry Approaches for Mold Identification

Retrieved on: 
Tuesday, January 17, 2023
Database, Infection, European Journal of Clinical Microbiology & Infectious Diseases, ASTA, Culture, Fungus, Korea, Professor, Diagnosis, Immunodeficiency, Patient, Journal, Chung-Ang University, Bias, Acquisition, Accuracy and precision, Medical imaging, Pharmaceutical industry, Medical device, Aspergillus

One such technique that can detect filamentous fungal isolates with high-sensitivity and reproducibility, is "matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)".

Key Points: 
  • One such technique that can detect filamentous fungal isolates with high-sensitivity and reproducibility, is "matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS)".
  • Recently, a team of researchers from Chung-Ang University, Republic of Korea led by Professor Mi-Kyung Lee, evaluated three different MALDI-TOF MS approaches used in domestic clinical settings, for the identification of molds.
  • Explaining the rationale behind their study, Prof. Lee remarks, "Selecting an appropriate sample preparation method can improve the efficiency and accuracy of mold identification.
  • Accurate results obtained through a simple and streamlined process for mold identification using MALDI-TOF MS could improve laboratory work efficiency for users and treatment efficiency for patients."

TVC Pro-Driver Named a Top Workplace in Oklahoma, Region

Retrieved on: 
Thursday, January 19, 2023
Legal, Other Transport, Trucking, Human Resources, Automotive, Transport, Professional Services, Logistics, Supply Chain Management, Fleet Management, CDL, The Journal Record, Organization, Philosophy, Journal, Research, TVC, Multimedia, Trial balance, Taxicab, Management

View the full release here: https://www.businesswire.com/news/home/20230119005894/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230119005894/en/
    The Journal Record named TVC Pro-Driver one of the 2022 Best Places to Work in Oklahoma.
  • TVC Pro-Driver was also named one of The Oklahoman’s Top Workplaces.
  • (Photo: Business Wire)
    TVC Pro-Driver was named a 2022 Top Workplaces Southwest Region Winner.
  • TVC Pro-Driver was also named one of The Journal Record’s Best Places to Work for the second year in a row.

New Clinical Study Finds Hydrafacial Clarifying Treatments Improve Acne Skin Concerns in 100 Percent of Participants

Retrieved on: 
Thursday, January 12, 2023
Cosmetics, Retail, Health, Clinical Trials, Journal, Hope, LED, Acne, Hand, SKIN, Beauty, Skin, Pharmaceutical industry, Cosmetics

Beloved professional skincare treatment Hydrafacial is now clinically reported to improve acne skin concerns, according to a new study published in the peer-reviewed Journal of Clinical and Aesthetic Dermatology (JCAD).

Key Points: 
  • Beloved professional skincare treatment Hydrafacial is now clinically reported to improve acne skin concerns, according to a new study published in the peer-reviewed Journal of Clinical and Aesthetic Dermatology (JCAD).
  • The Beauty Health Company-owned brand (NASDAQ: SKIN) shared that 100 percent of study participants reported clearer, less inflamed skin after a series of clarifying treatments with Hydrafacial’s patented vortex fusion device and blue LED light.
  • During the 12-week assessment, study participants, ranging in age from 19 to 48 and with varied skin tones, received a clarifying Hydrafacial treatment from a trained esthetician every two weeks.
  • All participants reported a significant improvement in acne severity, finding they had fewer acne lesions and cleaner, more radiant-looking skin.